Table 1.

Characteristics of 73 critically ill COVID-19 patients dying during ICU stay

	COVID-19 patients dying in ICU N = 73
Patient’s characteristics and ICU scores
Male sex	56 (77)
Age, years	68 [62–73]
SAPS II upon ICU admission	37 [29–45]
SOFA upon ICU admission	4 [3–8]
Main comorbidities
Arterial hypertension	52 (71)
Diabetes mellitus	35 (48)
Ischemic cardiopathy	10 (14)
Chronic respiratory disease	18 (25)
Immunocompromised status	18 (25)
Main delays
Days between disease onset and ICU admission	8 [6–11]
> 7 days between disease onset and ICU admission	51 (70)
Biological data upon ICU admission
D-dimers (ng/mL)	2505 [1555–5877]
Fibrinogen (g/L)	7.3 [5.6–8.5]
Treatment administered upon ICU admission
Glucocorticoids	35 (48)
Intermediate or full-dose thromboprophylaxis	53 (73)
Antibiotic therapy for bacterial co-infection at ICU admission	20 (27)
Antiviral drugs (lopinavir-ritonavir or remdesivir)	0 (0)
Tocilizumab	0 (0)
Outcome in the ICU
Invasive mechanical ventilation (IMV)	71 (97)
Days between ICU admission and IMV	2 [1–4]
Days between disease onset and IMV	11 [8–14]
Ventilator associated pneumonia	47 (64)
Prone positioning	62 (85)
Extra corporal membrane oxygenation	3 (4)
Tracheostomy	2 (3)
Renal replacement therapy	26 (36)
Vasopressor support	64 (88)
Thrombotic events during ICU stay	26 (36)
Hemorrhagic events during ICU stay	17 (23)
Delay between ICU admission and death, days	14 [9–23]

Continuous variables are reported as medians [quartile 1–quartile 3] and categorical variables are reported as numbers (percentages)

ACE/ARB Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers, ICU Intensive Care Unit, IMV Invasive Mechanical Ventilation, SAPS2 Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment